302 related articles for article (PubMed ID: 21087108)
1. Update on the current status of cytomegalovirus vaccines.
Sung H; Schleiss MR
Expert Rev Vaccines; 2010 Nov; 9(11):1303-14. PubMed ID: 21087108
[TBL] [Abstract][Full Text] [Related]
2. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
[TBL] [Abstract][Full Text] [Related]
3. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
Lilja AE; Mason PW
Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus Vaccines: Current Status and Future Prospects.
Anderholm KM; Bierle CJ; Schleiss MR
Drugs; 2016 Nov; 76(17):1625-1645. PubMed ID: 27882457
[TBL] [Abstract][Full Text] [Related]
5. A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.
Wussow F; Yue Y; Martinez J; Deere JD; Longmate J; Herrmann A; Barry PA; Diamond DJ
J Virol; 2013 Feb; 87(3):1322-32. PubMed ID: 23152525
[TBL] [Abstract][Full Text] [Related]
6. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
[TBL] [Abstract][Full Text] [Related]
7. Vaccine strategies against human cytomegalovirus infection.
Zhong J; Khanna R
Expert Rev Anti Infect Ther; 2007 Jun; 5(3):449-59. PubMed ID: 17547509
[TBL] [Abstract][Full Text] [Related]
8. Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.
Nelson CS; Vera Cruz D; Su M; Xie G; Vandergrift N; Pass RF; Forman M; Diener-West M; Koelle K; Arav-Boger R; Permar SR
J Virol; 2019 Mar; 93(5):. PubMed ID: 30518646
[TBL] [Abstract][Full Text] [Related]
9. Vaccination against cytomegalovirus.
Plotkin SA
Arch Virol Suppl; 2001; (17):121-34. PubMed ID: 11339541
[TBL] [Abstract][Full Text] [Related]
10. VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection.
Schleiss MR
Curr Opin Mol Ther; 2009 Oct; 11(5):572-8. PubMed ID: 19806506
[TBL] [Abstract][Full Text] [Related]
11. Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.
Cui X; Cao Z; Wang S; Lee RB; Wang X; Murata H; Adler SP; McVoy MA; Snapper CM
Vaccine; 2018 Sep; 36(37):5580-5590. PubMed ID: 30082162
[TBL] [Abstract][Full Text] [Related]
12. Vaccines for cytomegalovirus.
Bernstein DI
Infect Disord Drug Targets; 2011 Oct; 11(5):514-25. PubMed ID: 22309618
[TBL] [Abstract][Full Text] [Related]
13. Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine.
Gerna G; Lilleri D
New Microbiol; 2019 Jan; 42(1):1-20. PubMed ID: 30671581
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus vaccines.
McVoy MA
Clin Infect Dis; 2013 Dec; 57 Suppl 4(Suppl 4):S196-9. PubMed ID: 24257427
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus vaccines: at last, a major step forward.
Schleiss MR
Herpes; 2009 Jan; 15(3):44-5. PubMed ID: 19306601
[TBL] [Abstract][Full Text] [Related]
16. A Live Olfactory Mouse Cytomegalovirus Vaccine, Attenuated for Systemic Spread, Protects against Superinfection.
Farrell HE; Bruce K; Stevenson PG
J Virol; 2021 Oct; 95(21):e0126421. PubMed ID: 34431701
[TBL] [Abstract][Full Text] [Related]
17. Comparison of vaccine strategies against congenital CMV infection in the guinea pig model.
Schleiss MR
J Clin Virol; 2008 Mar; 41(3):224-30. PubMed ID: 18060834
[TBL] [Abstract][Full Text] [Related]
18. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.
Swanson EC; Gillis P; Hernandez-Alvarado N; Fernández-Alarcón C; Schmit M; Zabeli JC; Wussow F; Diamond DJ; Schleiss MR
Vaccine; 2015 Jul; 33(32):4013-8. PubMed ID: 26079615
[TBL] [Abstract][Full Text] [Related]
19. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.
Nelson CS; Huffman T; Jenks JA; Cisneros de la Rosa E; Xie G; Vandergrift N; Pass RF; Pollara J; Permar SR
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6267-6272. PubMed ID: 29712861
[TBL] [Abstract][Full Text] [Related]
20. Prospects of a vaccine for the prevention of congenital cytomegalovirus disease.
Plachter B
Med Microbiol Immunol; 2016 Dec; 205(6):537-547. PubMed ID: 27519596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
